Stemline Therapeutics (STML) PT Trimmed at Wedbush; Shares Remain Undervalued

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. MSFT
3. PLTR
4. SPY
5. CSCO
6. KTOS
7. JPM
8. DT
9. AON
10. TMUS

Go back to Stemline Therapeutics (STML) PT Trimmed at Wedbush; Shares Remain Undervalued

Stemline Therapeutics (STML) Misses Q4 EPS by 2c

March 16, 2015 7:12 AM EDT

Stemline Therapeutics (NASDAQ: STML) reported Q4 EPS of ($0.53), $0.02 worse than the analyst estimate of ($0.51).

Stemline ended the fourth quarter of 2014 with $58.6 million in cash, cash equivalents and investments, as compared to $65.0 million as of September 30, 2014. In January 2015, the Company completed an equity offering... More